Aeglea Bio Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview

Spyre Therapeutics

31/07/2023 19:35

* Aeglea Bio Therapeutics Inc  AGLE.OQ   AGLE.O  is expected
to show a fall in quarterly revenue when it reports  results on
August 2 (estimated). 
    * The Waltham Massachusetts-based  company is expected to
report 
a 84.2% decrease in revenue to $99 thousand from $625 thousand a
year ago, according to the mean estimate from 2 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Aeglea Bio
Therapeutics
Inc is for a loss of 16 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aeglea Bio
Therapeutics Inc is $0.9​, above​ its last closing price
of $0.58. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.19       -0.18      -0.20     Missed  -11.1
 Dec. 31 2023  -0.20       -0.20      -0.18     Beat    10
 Sep. 30 2022  -0.23       -0.23      -0.19     Beat    18.1​
 Jun. 30 2022  -0.31       -0.31      -0.27     Beat    13.4
 ​​Mar.        -0.33       -0.34      -0.37     Missed  -9.9
 31 2022                                                
 Dec. 31 2021              -0.29      -0.31     Missed  -8.5​
 Sep. 30 2021  -0.25       -0.28      -0.31     Missed  -11.3
 Jun. 30 2021  -0.18       -0.16      -0.10     Beat    39.1
 This summary was machine generated July 31 at 18:34 GMT.  All
figures in US dollars  unless otherwise stated